The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles

Biomaterials

Volumn 32, Issue 33, 2011, Pages 8538-8547

  Ateh, Davidson D ^a   Leinster, Veronica H ^a   Lambert, Sally R ^a   Shah, Afsha ^a   Khan, Ayub ^a   Walklin, Hazel J ^a   Johnstone, Jennifer V ^a   Ibrahim, Nader I ^a   Kadam, Mustafa M ^a   Malik, Zain ^a   Gironès, Míriam ^b   Veldhuis, Gert J ^b   Warnes, Gary ^a   Marino, Silvia ^a   McNeish, Iain A ^a   Martin, Joanne E ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NANOMI B V   (Netherlands)

Author keywords

Cancer; CD95; CD95L; Paclitaxel; Phagocytosis; Polylactic co glycolic acid

Indexed keywords

CANCER; CD95; CD95L; PACLITAXEL; PHAGOCYTOSIS; POLY LACTIC-CO-GLYCOLIC ACID;

ANTIGEN-ANTIBODY REACTIONS; BRAIN; CELL DEATH; DRUG DELIVERY; SURFACE TREATMENT; TUMORS;

DISEASES;

FAS ANTIGEN; FAS LIGAND; MICROSPHERE; PACLITAXEL; POLYGLACTIN;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; FLUORESCENCE ACTIVATED CELL SORTING; IN VIVO STUDY; MALE; MEDULLOBLASTOMA; MOUSE; NERVE CELL; NONHUMAN; OVARY CANCER; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; FLOW CYTOMETRY; HUMANS; LACTIC ACID; MICROSPHERES; PACLITAXEL; PHAGOCYTOSIS; POLYGLYCOLIC ACID;

EID: 80052970987     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.060     Document Type: Article

References (41)

1. Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365.
2. Nagata S., Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995, 16:39-43.
3. (GNF) TGIotNRF FAS (Fas (TNF receptor superfamily, member 6)) 2011, BioGPS gene annotation portal.
4. (GNF) TGIotNRF FASLG (Fas ligand (TNF superfamily, member 6)) 2011, BioGPS gene annotation portal.
5. Choi C., Benveniste E.N. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004, 44:65-81.
6. Landau A.M., Luk K.C., Jones M.L., Siegrist-Johnstone R., Young Y.K., Kouassi E., et al. Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. J Exp Med 2005, 202:575-581.
7. Ethell D.W., Kinloch R., Green D.R. Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. Curr Biol 2002, 12:1595-1600.
8. Ackery A., Robins S., Fehlings M.G. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J Neurotrauma 2006, 23:604-616.
9. O'Connell J., Houston A., Bennett M.W., O'Sullivan G.C., Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001, 7:271-274.
10. Ryan A.E., Shanahan F., O'Connell J., Houston A.M. Addressing the " Fas counterattack" controversy: blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005, 65:9817-9823.
11. Igney F.H., Krammer P.H. Tumor counterattack: fact or fiction?. Cancer Immunol Immunother 2005, 54:1127-1136.
12. Green D.R., Ferguson T.A. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001, 2:917-924.
13. Gratas C., Tohma Y., Van Meir E.G., Klein M., Tenan M., Ishii N., et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 1997, 7:863-869.
14. Weller M., Schuster M., Pietsch T., Schabet M. CD95 ligand-induced apoptosis of human medulloblastoma cells. Cancer Lett 1998, 128:121-126.
15. Abrahams V.M., Straszewski S.L., Kamsteeg M., Hanczaruk B., Schwartz P.E., Rutherford T.J., et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003, 63:5573-5581.
16. van Haaften-Day C., Russell P., Davies S., King N.J., Tattersall M.H. Expression of Fas and FasL in human serous ovarian epithelial tumors. Hum Pathol 2003, 34:74-79.
17. Munakata S., Enomoto T., Tsujimoto M., Otsuki Y., Miwa H., Kanno H., et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000, 82:1446-1452.
18. Kleber S., Sancho-Martinez I., Wiestler B., Beisel A., Gieffers C., Hill O., et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13:235-248.
19. Chen L., Park S.-M., Tumanov A.V., Hau A., Sawada K., Feig C., et al. CD95 promotes tumour growth. Nature 2010, 465:492-496.
20. Scheinberg D.A., Villa C.H., Escorcia F.E., McDevitt M.R. Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev Clin Oncol 2010, 7:266-276.
21. Rabinovitch M. Professional and non-professional phagocytes: an introduction. Trends Cell Biol 1995, 5:85-87.
22. Bowen S., Ateh D.D., Deinhardt K., Bird M.M., Price K.M., Baker C.S., et al. The phagocytic capacity of neurones. Eur J Neurosci 2007, 25:2947-2955.
23. Esselens C., Oorschot V., Baert V., Raemaekers T., Spittaels K., Serneels L., et al. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J Cell Biol 2004, 166:1041-1054.
24. van Meerbergen B., Raemaekers T., Winters K., Braeken D., Bartic C., Spira M., et al. Improving neuronal adhesion on chip using a phagocytosis-like event. J Exp Nanosci 2007, 2:101-114.
25. Cohen S., Yoshioka T., Lucarelli M., Hwang L.H., Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 1991, 8:713-720.
26. Ryan A.E., Lane S., Shanahan F., O'Connell J., Houston A.M. Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. J Carcinog 2006, 5:5.
27. Veldhuis G., Gironès M., Bingham D. Monodisperse microspheres for parenteral drug delivery. Drug Del Technol 2009, 9:24-31.
28. Benard J., Da Silva J., De Blois M.C., Boyer P., Duvillard P., Chiric E., et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985, 45:4970-4979.
29. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014.
30. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J Pathol 2005, 205:275-292.
31. Xiao K., Luo J., Fowler W.L., Li Y., Lee J.S., Xing L., et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 2009, 30:6006-6016.
32. Yao H.J., Ju R.J., Wang X.X., Zhang Y., Li R.J., Yu Y., et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 2011, 32:3285-3302.
33. Iqbal J., Sarti F., Perera G., Bernkop-Schnurch A. Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials 2011, 32:170-175.
34. Ingemarsdotter C.K., Baird S.K., Connell C.M., Oberg D., Hallden G., McNeish I.A. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 2010, 29:6051-6056.
35. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
36. Jaaback K., Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006, CD005340.
37. Bunting M., Chan W., Brand A., Blomfield P. Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned. Aust N Z J Obstet Gynaecol 2009, 49:667-671.
38. Katsumata N., Yasuda M., Takahashi F., Isonishi S., Jobo T., Aoki D., et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
39. Ma J., Reed K.A., Gallo J.M. Cells designed to deliver anticancer drugs by apoptosis. Cancer Res 2002, 62:1382-1387.
40. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103:6315-6320.
41. Chen W.C., Completo G.C., Sigal D.S., Crocker P.R., Saven A., Paulson J.C. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 2010, 115:4778-4786.